CTSO vs. LUCD, NSPR, APYX, AMIX, DRIO, XAIR, DXR, ICCM, GBS, and HSAQ
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Lucid Diagnostics (LUCD), InspireMD (NSPR), Apyx Medical (APYX), Autonomix Medical (AMIX), DarioHealth (DRIO), Beyond Air (XAIR), Daxor (DXR), IceCure Medical (ICCM), GBS (GBS), and Health Sciences Acquisitions Co. 2 (HSAQ). These companies are all part of the "surgical & medical instruments" industry.
Cytosorbents (NASDAQ:CTSO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
Cytosorbents has a net margin of -78.43% compared to Lucid Diagnostics' net margin of -2,169.07%. Cytosorbents' return on equity of -120.24% beat Lucid Diagnostics' return on equity.
Cytosorbents has higher revenue and earnings than Lucid Diagnostics. Cytosorbents is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Cytosorbents has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
Cytosorbents received 410 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. Likewise, 79.38% of users gave Cytosorbents an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
Cytosorbents currently has a consensus target price of $2.50, indicating a potential upside of 194.12%. Lucid Diagnostics has a consensus target price of $2.75, indicating a potential upside of 192.96%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than Lucid Diagnostics.
In the previous week, Cytosorbents had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for Cytosorbents and 3 mentions for Lucid Diagnostics. Cytosorbents' average media sentiment score of 0.05 beat Lucid Diagnostics' score of 0.00 indicating that Cytosorbents is being referred to more favorably in the media.
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 6.6% of Cytosorbents shares are held by company insiders. Comparatively, 4.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Cytosorbents beats Lucid Diagnostics on 12 of the 18 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
